BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30188361)

  • 21. SMARCA4-deficient lung carcinoma is an aggressive tumor highly infiltrated by FOXP3+ cells and neutrophils.
    Velut Y; Decroix E; Blons H; Alifano M; Leroy K; Petitprez F; Boni A; Garinet S; Biton J; Cremer I; Wislez M; Boudou-Rouquette P; Arrondeau J; Goldwasser F; Fournel L; Damotte D; Mansuet-Lupo A
    Lung Cancer; 2022 Jul; 169():13-21. PubMed ID: 35597058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive markers in lung cancer: a few hints for the practicing pathologist.
    Barbareschi M; Barberis M; Buttitta F; Doglioni C; Fiorentino M; Fontanini G; Franco R; Marchetti A; Rossi G; Troncone G
    Pathologica; 2018 Mar; 110(1):29-38. PubMed ID: 30259911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The Current Immunohistochemistry Markers in the Resected Tissues of Non-small Cell Lung Cancer Could Not Predict Prognosis].
    Shen L; Kang X; Sun Y; Fu H; Dai L; Yan W; Chen K
    Zhongguo Fei Ai Za Zhi; 2016 Mar; 19(3):147-52. PubMed ID: 27009819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
    Luk PP; Selinger CI; Mahar A; Cooper WA
    Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.
    Sigel CS; Moreira AL; Travis WD; Zakowski MF; Thornton RH; Riely GJ; Rekhtman N
    J Thorac Oncol; 2011 Nov; 6(11):1849-56. PubMed ID: 21841504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung Carcinoma Predictive Biomarker Testing by Immunoperoxidase Stains in Cytology and Small Biopsy Specimens: Advantages and Limitations.
    Zhou F; Moreira AL
    Arch Pathol Lab Med; 2016 Dec; 140(12):1331-1337. PubMed ID: 27588333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer.
    Raz G; Allen KE; Kingsley C; Cherni I; Arora S; Watanabe A; Lorenzo CD; Edwards V DK; Sridhar S; Hostetter G; Weiss GJ
    Lung Cancer; 2012 May; 76(2):191-6. PubMed ID: 22115706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection.
    Jiang W; Pang XG; Wang Q; Shen YX; Chen XK; Xi JJ
    Clin Lung Cancer; 2012 Jul; 13(4):280-7. PubMed ID: 22178381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC).
    Shen Q; Wang X; Yu B; Shi S; Liu B; Wang Y; Xia Q; Rao Q; Zhou X
    Lung Cancer; 2015 Dec; 90(3):492-8. PubMed ID: 26477969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
    Vlajnic T; Savic S; Barascud A; Baschiera B; Bihl M; Grilli B; Herzog M; Rebetez J; Bubendorf L
    Cancer Cytopathol; 2018 Jun; 126(6):421-429. PubMed ID: 29451745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens.
    Herpel E; Rieker RJ; Dienemann H; Muley T; Meister M; Hartmann A; Warth A; Agaimy A
    Ann Diagn Pathol; 2017 Feb; 26():47-51. PubMed ID: 28038711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
    Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
    Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.
    Nicholson AG; Gonzalez D; Shah P; Pynegar MJ; Deshmukh M; Rice A; Popat S
    J Thorac Oncol; 2010 Apr; 5(4):436-41. PubMed ID: 20068475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Negative NKX2-1 (TTF-1) as temporary surrogate marker for treatment selection during EGFR-mutation analysis in patients with non-small-cell lung cancer.
    Vincenten J; Smit EF; Vos W; Grünberg K; Postmus PE; Heideman DA; Snijders PJ; Meijer G; Kuik J; Witte BI; Thunnissen E
    J Thorac Oncol; 2012 Oct; 7(10):1522-7. PubMed ID: 22982653
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SMARCA4 as a support for the differential diagnosis of poorly differentiated lung carcinomas.
    Panozzi M; Alì G; Proietti A; Melfi F; Zirafa CC; Lucchi M; Fontanini G
    Pathologica; 2023 Jun; 115(3):164-171. PubMed ID: 37387441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives and Issues in the Assessment of
    Armon S; Hofman P; Ilié M
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
    Yatabe Y; Dacic S; Borczuk AC; Warth A; Russell PA; Lantuejoul S; Beasley MB; Thunnissen E; Pelosi G; Rekhtman N; Bubendorf L; Mino-Kenudson M; Yoshida A; Geisinger KR; Noguchi M; Chirieac LR; Bolting J; Chung JH; Chou TY; Chen G; Poleri C; Lopez-Rios F; Papotti M; Sholl LM; Roden AC; Travis WD; Hirsch FR; Kerr KM; Tsao MS; Nicholson AG; Wistuba I; Moreira AL
    J Thorac Oncol; 2019 Mar; 14(3):377-407. PubMed ID: 30572031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.